Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.

Source:http://linkedlifedata.com/resource/pubmed/id/15256463

Cancer Res. 2004 Jul 15 64 14 4912-8

Download in:

View as

Triples

General Info

PMID
15256463